Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.

@article{Bonifazi2019AcuteGP,
  title={Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.},
  author={Francesca Bonifazi and Carlos Solano and Christine Wolschke and Mariarosaria Sessa and Francesca Patriarca and Francesco Zallio and Arnon Nagler and Carmine Selleri and Antonio Maria Risitano and Giuseppe Messina and Wolfgang Andreas Bethge and Pilar Herrera and Anna Sureda and Angelo Michele Carella and Michele Cimminiello and Stefano Guidi and J{\"u}rgen Finke and Roberto Sorasio and Christelle Ferr{\'a} and Jorge Sierra and Domenico Russo and Edoardo Benedetti and Giuseppe Milone and Fabio M. Benedetti and Marion Heinzelmann and Domenico Pastore and Manuel Jurado and Elisabetta Terruzzi and Franco Narni and Andreas V{\"o}lp and Francis Ayuk and Tapani Ruutu and Nicolaus Kr{\"o}ger},
  journal={The Lancet. Haematology},
  year={2019},
  volume={6 2},
  pages={
          e89-e99
        }
}

Figures from this paper

Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors

It is confirmed that PTCy+T/MMF treatment effectively prevented acute and chronic GVHD and limited NRM to unprecedented low rates without loss of disease control efficacy in an expanded patient cohort.

Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant Transplantation and Cellular Therapy

Sirolimus-PTCy platform deserves further investigation as an alternative to calcineurin-inhibitor (cid:1) based GVHD prophylaxis for all donor sources and in patients presenting a low-intermediate DRI, this strategy translates in relevant survival independently from the transplant source.

Reduced Risk of Chronic Graft-Versus-Host Disease (cGVHD) by Rabbit Anti-Thymocyte Globulin (ATG) in Patients Undergoing Matched Sibling Donor Transplantation in Hematological Malignancies

ATG in the strategy was effective for prophylaxis of cGVHD, whereas the relapse rate was increased in patients with rATG, and ATG was an independent poor risk factor for CIR.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT to prevent graft-versus-host disease.

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation

The choice of ATLG dose has significant impact on IR but not on GVHD after MUD-allo-SCT, and higher doses are associated with delayed engraftment and increased infections.

Role of antithymocyte globulin in matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies

Rabbit antithymocyte globulin in the current protocol for GVHD prophylaxis was well tolerable and efficacious and led to a significant reduction in the incidence of cGVHD without increased relapse risk and nonrelapse mortality.

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study

PT-Cy and ATLG was overall safe and translated into a low rate of chronic GvHD incidence, and long-term immune reconstitution on the CD4+ subsets did not translate into higher rate of relapse or viral infection.

Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors

It is shown that low-dose ATG effectively suppresses chronic GVHD in unrelated PBSCT, and ALC before ATG may be a potential predictor for GV HD and relapse.

Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

  • A. SalhotraS. Hui A. Stein
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2019

References

SHOWING 1-10 OF 35 REFERENCES

Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

The results suggest that the use of ATG with fludarabine and 4 days intravenous busulfan followed by HLA-identical sibling donor allogeneic stem cell transplantation for acute myeloid leukemia improves overall transplant outcomes due to reduced incidence of chronic GVHD without increased relapse risk.

Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel

Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT to prevent graft-versus-host disease.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.

The inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia resulted in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

Data suggest that posttransplantation cyclophosphamide (PTCy) minimizes the global immunosuppressive burden experienced by patients undergoing HLA-matched alloBMT.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

A prospective, double-blind phase III trial to investigate the effect of ATLG on cGVHD-free survival found that in vivo T-cell depletion with anti-T-lymphocyte globulin reduces chronic graft-versus-host disease (cGVHD) without compromising survival.